Financial Contrast: Allakos (NASDAQ:ALLK) versus CNBX Pharmaceuticals (OTCMKTS:CNBX)

Allakos (NASDAQ:ALLK) and CNBX Pharmaceuticals (OTCMKTS:CNBX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Allakos and CNBX Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allakos	1	2	2	0	2.20
CNBX Pharmaceuticals	0	0	0	0	N/A

Allakos presently has a consensus price target of $1.67, suggesting a potential upside of 137.08%. Given Allakos’ higher possible upside, equities analysts plainly believe Allakos is more favorable than CNBX Pharmaceuticals.

Earnings and Valuation

This table compares Allakos and CNBX Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allakos	N/A	N/A	-$185.70 million	($2.45)	-0.29
CNBX Pharmaceuticals	N/A	N/A	N/A	($0.01)	-1.28

CNBX Pharmaceuticals is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Allakos and CNBX Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allakos	N/A	-99.88%	-73.06%
CNBX Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

84.6% of Allakos shares are owned by institutional investors. Comparatively, 98.2% of CNBX Pharmaceuticals shares are owned by institutional investors. 16.1% of Allakos shares are owned by company insiders. Comparatively, 73.5% of CNBX Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CNBX Pharmaceuticals beats Allakos on 5 of the 8 factors compared between the two stocks.

About Allakos

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.